William Blair Analysts Lower Earnings Estimates for Harrow

Key Points

• William Blair analysts have lowered their Q3 2025 EPS estimate for Harrow, Inc. from $0.13 to $0.07 per share, while maintaining an "Outperform" rating on the stock.
• The consensus estimate for Harrow's full-year earnings currently stands at ($0.53) per share, highlighting ongoing financial challenges for the company.
• Institutional ownership is significant, with 72.76% of shares held by hedge funds and other institutional investors, indicating strong institutional interest in the stock.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Investment analysts at William Blair cut their Q3 2025 EPS estimates for shares of Harrow in a research report issued on Tuesday, September 9th. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn $0.07 per share for the quarter, down from their prior estimate of $0.13. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow's Q4 2025 earnings at $0.36 EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at $0.44 EPS, Q3 2026 earnings at $0.40 EPS and Q4 2026 earnings at $0.76 EPS.

Harrow (NASDAQ:HROW - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.23. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. The business had revenue of $63.74 million during the quarter, compared to analyst estimates of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

A number of other equities research analysts have also commented on HROW. BTIG Research upped their price target on shares of Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a report on Thursday, August 14th. Zacks Research raised shares of Harrow from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. Cantor Fitzgerald started coverage on shares of Harrow in a research report on Friday, July 11th. They set an "overweight" rating and a $76.00 price objective on the stock. Finally, HC Wainwright boosted their price objective on shares of Harrow from $60.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. One investment analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $64.67.

Harrow Trading Down 1.1%

Shares of HROW opened at $38.87 on Thursday. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -155.48 and a beta of 0.33. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.58 and a current ratio of 0.62. Harrow has a fifty-two week low of $20.85 and a fifty-two week high of $59.23. The firm has a 50 day moving average price of $35.81 and a 200-day moving average price of $29.84.

Institutional Trading of Harrow

Several institutional investors have recently bought and sold shares of the company. Braidwell LP grew its position in Harrow by 5.5% during the 1st quarter. Braidwell LP now owns 956,839 shares of the company's stock valued at $25,452,000 after purchasing an additional 49,800 shares during the last quarter. Geode Capital Management LLC grew its position in Harrow by 4.7% during the 2nd quarter. Geode Capital Management LLC now owns 810,803 shares of the company's stock valued at $24,765,000 after purchasing an additional 36,724 shares during the last quarter. Marshall Wace LLP grew its position in Harrow by 31.5% during the 2nd quarter. Marshall Wace LLP now owns 564,876 shares of the company's stock valued at $17,251,000 after purchasing an additional 135,202 shares during the last quarter. Voya Investment Management LLC grew its position in Harrow by 4,035.5% during the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock valued at $10,147,000 after purchasing an additional 372,237 shares during the last quarter. Finally, Royce & Associates LP lifted its stake in Harrow by 12.0% during the 1st quarter. Royce & Associates LP now owns 327,096 shares of the company's stock valued at $8,701,000 after acquiring an additional 35,006 shares during the period. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.